Public Health And Economic Impact of A Quadrivalent Influenza Vaccine In Comparison to The Trivalent Influenza Vaccine In Brazil Over The Period Of 2010 – 2013

Bricks, Lúcia Ferro; Lopez, JG; Macabéo, Bérengère; Piedade, A; Clark, O.A.C.; Nishikawa, A.M.; Bottoni, Adriana; Gonçalves, Thiago de Menezes

doi:10.1016/j.jval.2015.09.1927

Cited by 1 publication

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 8 The CDC model was adapted and used to assess the cost of switching from trivalent to quadrivalent vaccines from a Brazilian healthcare and societal perspective from 2010 to 2013. 33 It was estimated that the use of quadrivalent instead of trivalent vaccine in Brazil would have reduced the number of influenza cases by 654,018, reduced the number of hospitalizations by 7536, and reduced influenza-related deaths by 1122. In 2013 when the rate of mismatch of IIV3 with the circulating influenza B strain was >90%, the model showed that quadrivalent vaccine could have avoided influenza-related costs of R$ 1 million to the health system and R$ 62 million to society.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil

Zerbini

Santos

Nunes

et al. 2017

The Brazilian Journal of Infectious Diseases

View full text Add to dashboard Cite

The World Health Organization influenza forecast now includes an influenza B strain from each of the influenza B lineages (B/Yamagata and B/Victoria) for inclusion in seasonal influenza vaccines. Traditional trivalent influenza vaccines include an influenza B strain from one lineage, but because two influenza B lineages frequently co-circulate, the effectiveness of trivalent vaccines may be reduced in seasons of influenza B vaccine-mismatch. Thus, quadrivalent vaccines may potentially reduce the burden of influenza compared with trivalent vaccines. In this Phase III, open-label study, we assessed the immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine (Fluarix™ Tetra) in Brazilian adults (NCT02369341). The primary objective was to assess hemagglutination-inhibition antibody responses against each vaccine strain 21 days after vaccination in adults (aged ≥18-60 years) and older adults (aged >60 years). Solicited adverse events for four days post-vaccination, and unsolicited adverse events and serious adverse events for 21 days post-vaccination were also assessed. A total of 63 adults and 57 older adults received one dose of inactivated quadrivalent influenza vaccine at the beginning of the 2015 Southern Hemisphere influenza season. After vaccination, in adults and older adults, the hemagglutination-inhibition titers fulfilled the European licensure criteria for immunogenicity. In adults, the seroprotection rates with HI titer ≥1:40 were 100% (A/H1N1), 98.4% (A/H3N2), 100% (B/Yamagata), and 100% (B/Victoria); in older adults were 94.7% (A/H1N1), 96.5% (A/H3N2), 100% (B/Yamagata), and 100% (B/Victoria). Pain was the most common solicited local adverse events in adults (27/62) and in older adults (13/57), and the most common solicited general adverse events in adults was myalgia (9/62), and in older adults were myalgia and arthralgia (both 2/57). Unsolicited adverse events were reported by 11/63 adults and 10/57 older adults. The study showed that inactivated quadrivalent influenza vaccine was immunogenic and well-tolerated in Brazilian adults and older adults.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In 2013 when the rate of mismatch of IIV3 with the circulating influenza B strain was >90%, the model showed that quadrivalent vaccine could have avoided influenza-related costs of R$ 1 million to the health system and R$ 62 million to society. 33 …”

Section: Discussionmentioning

confidence: 99%